★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
GSK plc
GSK · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
GSK plc is a global biopharma company focused on Specialty Medicines, Vaccines, and General Medicines. FY2025 growth shifted mix toward Specialty Medicines, especially HIV, respiratory/immunology and oncology, while Q1 2026 continued that pattern with Specialty Medicines sales up 14% CER, Vaccines up 4%, and General Medicines down 6%. The strongest company-specific moat is time-bounded patent and related exclusivity protection around products including Shingrix, Dovato and Trelegy. Respiratory devices add modest patient and clinician retraining friction, although payers can override it. Revenue scale, a single pipeline asset and regulatory compliance do not separately establish a moat because capable peers share those characteristics. Key risks are patent cliffs, vaccine demand volatility, reimbursement pressure and pipeline execution.
Primary segment
Specialty Medicines
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
3 segments · 5 tags
Updated 2026-07-11
Segments
Vaccines
Human vaccines
Revenue
28%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Specialty Medicines
Branded specialty pharmaceuticals (HIV, oncology, immunology/respiratory)
Revenue
41.2%
Structure
Oligopoly
Pricing
strong
Share
—
Peers
General Medicines
Respiratory inhaled therapies and established branded medicines
Revenue
30.7%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Moat Claims
Vaccines
Human vaccines
FY2025 Vaccines turnover was GBP9.157bn, or 28.0% of Commercial Operations turnover. Q1 2026 Vaccines sales were GBP2.1bn, +4% CER, with Shingrix +20%, meningitis vaccines -3%, and Arexvy -18%. Sources: https://www.gsk.com/media/3rxjw5di/investor-information-2025.pdf and https://www.gsk.com/media/hpgfxwxv/q1-2026-results-announcement.pdf.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents/exclusivities on key adult vaccines support differentiation, but protection is time-bounded and Arexvy is already facing weaker US demand after its post-launch surge.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent expiry and biosimilar/next-gen vaccine entry
- Competitors improving safety/efficacy profiles
- Government tender pricing reducing returns despite IP
Leading indicators
- Competitor trial readouts in overlapping indications
- Patent challenges or adverse litigation outcomes
- ACIP/EMA label and recommendation changes
Counterarguments
- Vaccine IP does not guarantee sustained share if rivals launch better products
- Tender-driven markets can commoditize even differentiated vaccines
Specialty Medicines
Branded specialty pharmaceuticals (HIV, oncology, immunology/respiratory)
FY2025 Specialty Medicines turnover was GBP13.474bn, or 41.2% of Commercial Operations turnover, led by HIV GBP7.687bn, RI&I GBP3.810bn and Oncology GBP1.977bn. Q1 2026 Specialty Medicines sales were GBP3.2bn, +14% CER. Sources: https://www.gsk.com/media/3rxjw5di/investor-information-2025.pdf and https://www.gsk.com/media/hpgfxwxv/q1-2026-results-announcement.pdf.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Core earnings power is increasingly tied to patent-protected specialty assets, notably HIV, respiratory/immunology and oncology, that restrict generic competition during exclusivity windows.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Loss of exclusivity and generic/biosimilar entry
- Price controls and reimbursement tightening
- Clinical differentiation narrowing vs competitors
Leading indicators
- Patent litigation outcomes and generic filing activity
- Payer/formulary moves against branded regimens
- Share shifts in HIV and oncology classes
Counterarguments
- Even under patent, payers can steer volume to alternatives
- Pipeline execution is required to replace revenue at LOE
General Medicines
Respiratory inhaled therapies and established branded medicines
FY2025 General Medicines turnover was GBP10.036bn, or 30.7% of Commercial Operations turnover, with respiratory GBP7.068bn and Trelegy GBP2.986bn. Q1 2026 General Medicines sales were GBP2.3bn, -6% CER, with Trelegy GBP0.6bn stable. Sources: https://www.gsk.com/media/3rxjw5di/investor-information-2025.pdf and https://www.gsk.com/media/hpgfxwxv/q1-2026-results-announcement.pdf.
Switching Costs General
Demand
Switching Costs General
Strength
Durability
Confidence
Evidence
Respiratory-device technique and patient training create modest friction when changing inhaler platforms. The effect is clinically relevant but not exclusive to GSK and can be overridden by payer formulary decisions.
Switching Costs General moat: definition, examples, and stocks
Erosion risks
- Payers force non-medical switches
- Generic and therapeutically similar inhalers reduce differentiation
- Digital training and device standardization reduce technique barriers
Leading indicators
- Formulary exclusions and rebate pressure
- Generic entry and substitution rates
- Adherence and persistence metrics for inhaled therapies
Counterarguments
- Clinicians can retrain patients and switching remains feasible
- Insurers can override patient or provider preference through formularies
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Trelegy retains some patent protection and remains a key respiratory growth driver, but many older general medicines face generic competition.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent expiry and generic/biosimilar entry
- Device patent workarounds by competitors
- Pricing pressure via payer rebates
Leading indicators
- Patent challenges and settlements
- Competitor inhaler launches and generic approvals
- Net price trends (rebate/discount intensity)
Counterarguments
- Even with patents, payers can compress net pricing through rebates
- Competitors can launch therapeutically similar combinations
Evidence
Shingrix zoster vaccine recombinant, adjuvanted
The 2025 patent table lists Shingrix patent expiry as 2029 in the US and 2031 in the EU.
Dovato dolutegravir, lamivudine HIV/AIDS
The 2025 patent table lists Dovato patent expiries/ranges through 2028-2034 across territories.
Patients who are switched from one device to another are more likely to have poor inhaler technique and disease control.
Directly supports a real organizational and patient retraining cost when changing inhaler devices.
Trelegy Ellipta fluticasone furoate/vilanterol trifenatate/umeclidinium bromide
The 2025 patent table lists Trelegy protection through 2027-2031 in the US and 2026-2032 in the EU.
Risks & Indicators
Erosion risks
- Patent expiry and biosimilar/next-gen vaccine entry
- Competitors improving safety/efficacy profiles
- Government tender pricing reducing returns despite IP
- Loss of exclusivity and generic/biosimilar entry
- Price controls and reimbursement tightening
- Clinical differentiation narrowing vs competitors
Leading indicators
- Competitor trial readouts in overlapping indications
- Patent challenges or adverse litigation outcomes
- ACIP/EMA label and recommendation changes
- Patent litigation outcomes and generic filing activity
- Payer/formulary moves against branded regimens
- Share shifts in HIV and oncology classes
Research GSK elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.